Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 1

Status

Completed 6

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 9Tumor-Agnostic 6Gynecologic 4Other solid neoplasm 3Genitourinary 2Other hematologic neoplasm 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 6

Interventions

pembrolizumab 46Paclitaxel 46Gemcitabine 41Carboplatin 37Docetaxel 35Bevacizumab 27Cisplatin 25Irinotecan 22Nivolumab 20Fluorouracil 20Erlotinib Hydrochloride 18Pemetrexed 17Capecitabine 17Sorafenib 16Magnetic Resonance Spectroscopy 16Cetuximab 16Afatinib 16Leucovorin 15regorafenib 14olaparib 13Specimen Handling 13Oxaliplatin 13trametinib 12Biopsy 12130-nm albumin-bound paclitaxel 11eribulin 10atezolizumab 10epothilone B 9Radiotherapy 9Midazolam 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × nintedanib × Tumor-Agnostic × Clear all
NCT01022853 2018-07-30

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

Boehringer Ingelheim

Phase 1 Completed
30 enrolled 24 charts
Tumor-Agnostic

Neoplasms

NCT00998296 2015-08-19

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

Boehringer Ingelheim

Phase 1 Completed
70 enrolled 25 charts
Tumor-Agnostic

Neoplasms

NCT00715403 2014-12-02

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

Boehringer Ingelheim

Phase 1 Completed
41 enrolled 24 charts
Tumor-Agnostic

Neoplasms

NCT02182128 2014-07-18

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

Boehringer Ingelheim

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

NCT02182206 2014-07-18

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

Boehringer Ingelheim

Phase 1 Completed
50 enrolled
Tumor-Agnostic

Neoplasms

NCT00730821 2009-08-21

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

Boehringer Ingelheim

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡